The evaluation of these molecules as inhibitors on a mammalian kinases panel revealed that several compounds (5, 6, 10 and 11) exhibit marked activities against CDK5, CK1 and DYRK1A, a set of kinases involved in several neuronal pathologies such as Down Syndrome and Alzheimer’s disease. The gene discussed is CDK5; the disease is early-onset autosomal dominant Alzheimer disease.